Softwr

Research · head to head

Form Bio vs Suzy

Form Bio logo

Form Bio

Research

Computational platform for cell and gene therapy design and manufacturability

From
On request
Rated
-
Full reviewWebsite
Suzy logo

Suzy

Research

Enterprise consumer insights on an owned US panel, resold elsewhere through Cint

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.; Suzy the proprietary Crowdtap panel is US only at around a million consumers with roughly 50,000 verified active monthly, and everything international is resold Cint supply, so the speed and verification argument that justifies the price applies to one market.
  • They diverge on capability: Form Bio covers FormManufacturing, Suzy covers Suzy Insights.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Form Bio and Suzy actually diverge.

Attributes where Form Bio and Suzy differ
AttributeForm BioSuzy
PlatformsWeb, CloudWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Form Bio

  • FormManufacturing
  • Payload design optimisation
  • Genome integrity analysis
  • Manufacturability prediction
  • In silico workflows
  • Scale-up monitoring
  • Cell and gene therapy focus
  • Collaboration

Only in Suzy

  • Suzy Insights
  • Suzy Live
  • Suzy Audiences
  • Suzy Speaks
  • Video open ends
  • Advanced methods
  • Data Explorer
  • AI Decision Engine

What people use each for

The jobs each tool is most often brought in to do.

Form Bio

  • A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot Suzy
  • A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot Suzy
  • A CDMO characterising what a client construct actually produces against what was specifiednot Suzy
  • A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot Suzy

Suzy

  • A US consumer packaged goods brand that needs concept testing back the same day because a packaging decision is due at the end of the week.not Form Bio
  • An insights department running an always-on brand tracker on a US audience without re-commissioning fieldwork every wave.not Form Bio
  • A team that wants quant screening followed immediately by moderated qual with the same respondents, rather than two vendors and two timelines.not Form Bio
  • A product team testing claims and price sensitivity with MaxDiff and conjoint on a panel they can go back to repeatedly.not Form Bio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Form Bio

  • The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
  • The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
  • No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
  • This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
  • Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.

Suzy

  • The proprietary Crowdtap panel is US only at around a million consumers with roughly 50,000 verified active monthly, and everything international is resold Cint supply, so the speed and verification argument that justifies the price applies to one market.
  • Customers have asked Suzy to build proprietary panels with native speakers in Germany, France, Japan, India and Brazil, which confirms those do not exist today; multi-market brands need a second vendor and lose the single-source comparison.
  • Reviewers report the panel skews female and millennial and falls short on Gen Z, male and various ethnic segments, and that niche or B2B audiences are hard to reach, so quota fills can be slow or impossible.
  • Reviewers also raise data trust concerns about respondent sourcing and vetting, including one naming bot responses and acquiescence bias, which is the standing risk of any single owned opt-in panel with repeat respondents.
  • Pricing is a sales-led annual commitment reported to run around $88,000 a year at the median with onboarding fees and per-seat charges on top, with no trial, no self-serve and no pay-per-response option, so there is no cheap way to validate fit.
  • Credits are pre-committed monthly against forecast activity with no published overage rate, so under-use is wasted spend and a busy quarter triggers an unbudgeted purchase.
  • Integrations are genuinely thin: there is no public integrations page and no public API documentation, and the only confirmed external data relationship is Cint, so expect to move data by export.

Pricing, plan by plan

Form Bio

On request
  • FormManufacturing$undefined/year
    • Pricing only through a sales process
    • Scoped per therapeutic programme rather than per seat
    • AAV-focused offering at launch

Suzy

On request
  • Suzy$undefined/year
    • Annual subscription with pre-committed monthly research credits
    • Credit volume set against forecast study activity
    • Onboarding fees and per-seat charges quoted separately

Which should you pick?

Choose Form Bio if

  • You need formmanufacturing.
  • You work on Web, Cloud.
  • You also want payload design optimisation.
Form Bio review

Choose Suzy if

  • You need suzy insights.
  • You work on Web, iOS, Android.
  • You also want suzy live.
Suzy review

Questions people ask

Is Form Bio or Suzy better?
Neither clearly leads. Form Bio starts at On request and Suzy at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Form Bio or Suzy?
Form Bio starts at On request and Suzy at On request.
Does Form Bio or Suzy run on more platforms?
Form Bio runs on Web, Cloud. Suzy runs on Web, iOS, Android.
What is Form Bio best used for?
Form Bio is most often used for a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier, a biotech comparing several candidate payload designs in silico before committing to expensive production runs, a cdmo characterising what a client construct actually produces against what was specified, a programme team needing genome integrity evidence to support regulatory conversations about product consistency. Of those, a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier and a biotech comparing several candidate payload designs in silico before committing to expensive production runs are not what Suzy is typically brought in for.
What can Form Bio do that Suzy cannot?
Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction. Suzy covers Suzy Insights, Suzy Live, Suzy Audiences, Suzy Speaks.

Answered from the vendors’ own pages

Form Bio: What does Form Bio sell now?

FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.

Suzy: Is the panel global?

No. Crowdtap, the owned panel, is US only. International studies run on Cint supply, which you could contract for directly.

Form Bio: Is it still a general bioinformatics platform?

No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.

Suzy: What does it cost?

Nothing is published. Third-party analysis puts the median contract around $88,000 a year with a range roughly $34,000 to $187,500, plus onboarding and per-seat fees.

Form Bio: Where did the company come from?

It spun out of Colossal Biosciences in 2022.

Suzy: Is there an API?

Nothing public. Suzy publishes no API documentation and no named connectors beyond Cint. Verify any integration requirement in the sales call before committing.

Form Bio: Is pricing published?

No. Engagements are scoped per programme through a sales process.

Suzy: What changed in April 2026?

Suzy repositioned as an AI Decision Engine with Intelligence and Impact modules, while headcount fell from about 230 to 186. Ask how the roadmap is now split between that and the classic survey and qual products.

Share

Related pages

More on Form Bio

More on Suzy

Keep looking

Other head to heads